Trushenko Natalia V, Suvorova Olga A, Pershina Ekaterina S, Nekludova Galina V, Chikina Svetlana Yu, Levina Iuliia A, Chernyaev Andrey L, Samsonova Maria V, Tyurin Igor E, Mustafina Malika Kh, Yaroshetskiy Andrey I, Nadtochiy Nikita B, Merzhoeva Zamira M, Proshkina Anna A, Avdeev Sergey N
Pulmonology Department, Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Trubetskaya St. 8, Build. 2, 119991 Moscow, Russia.
Pulmonology Scientific Research Institute, Federal Medical and Biological Agency of Russian Federation, Orekhovyy Boulevard 28, 115682 Moscow, Russia.
Life (Basel). 2023 Feb 8;13(2):467. doi: 10.3390/life13020467.
Hypersensitivity pneumonitis (HP) is an interstitial lung disease (ILD) resulting from an immune-mediated response in susceptible and sensitized individuals to a large variety of inhaled antigens. Chronic HP with a fibrotic phenotype is characterized by disease progression and a dismal prognosis. The aim of this study was to identify predictors of progression and mortality in patients with chronic HP in real clinical practice.
This retrospective, multicenter, observational study used data from a registry of 1355 patients with fibrosing ILDs. The study included 292 patients diagnosed with chronic HP based on the conclusion of a multidisciplinary discussion (MDD).
The patients were divided into groups with progressive (92 (30.3%) patients) and nonprogressive pulmonary fibrosis (200 (69.7%) patients). The most significant predictors of adverse outcomes were a DLco < 50% predicted, an SpO2 at the end of a six-minute walk test (6-MWT) < 85%, and a GAP score ≥ 4 points.
Pulmonary fibrosis and a progressive fibrotic phenotype are common in patients with chronic HP. Early detection of the predictors of an adverse prognosis of chronic HP is necessary for the timely initiation of antifibrotic therapy.
过敏性肺炎(HP)是一种间质性肺疾病(ILD),由易感且致敏个体对多种吸入性抗原产生的免疫介导反应引起。具有纤维化表型的慢性HP的特征是疾病进展和预后不良。本研究的目的是在实际临床实践中确定慢性HP患者病情进展和死亡的预测因素。
这项回顾性、多中心观察性研究使用了来自1355例纤维化ILD患者登记处的数据。该研究纳入了292例根据多学科讨论(MDD)结论诊断为慢性HP的患者。
患者被分为肺纤维化进展组(92例(30.3%)患者)和非进展组(200例(69.7%)患者)。不良结局的最显著预测因素是预计DLco<50%、六分钟步行试验(6-MWT)结束时SpO2<85%以及GAP评分≥4分。
肺纤维化和进行性纤维化表型在慢性HP患者中很常见。早期发现慢性HP不良预后的预测因素对于及时启动抗纤维化治疗很有必要。